Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P12814
UPID:
ACTN1_HUMAN
Alternative names:
Alpha-actinin cytoskeletal isoform; F-actin cross-linking protein; Non-muscle alpha-actinin-1
Alternative UPACC:
P12814; B3V8S3; B4DHH3; B7TY16; Q1HE25; Q9BTN1
Background:
Alpha-actinin-1, identified by the accession number P12814, serves as a pivotal F-actin cross-linking protein. It plays a crucial role in anchoring actin to various intracellular structures, acting as a bundling protein. Known by alternative names such as Alpha-actinin cytoskeletal isoform and Non-muscle alpha-actinin-1, it is integral to the cytoskeletal architecture.
Therapeutic significance:
The protein is linked to Bleeding disorder, platelet-type, 15, a condition characterized by macrothrombocytopenia with minimal bleeding tendencies. Understanding the role of Alpha-actinin-1 in this disorder could pave the way for innovative therapeutic strategies targeting the underlying genetic variants.